Semaglutide: a physician-grade reading of the GLP-1 receptor evidence, trial by trial.

Semaglutide produced mean body weight reduction of 14.9% in adults with obesity over 68 weeks in the STEP 1 trial — roughly six times the 2.4% recorded with placebo in the same study.^[1] That headline number comes from a 1,961-person randomized controlled trial published in the New England Journal of Medicine; 86.4% of semaglutide-treated participants achieved at least 5% weight loss versus 31.5% on placebo.

Semaglutide is a 31-amino-acid glucagon-like peptide-1 analogue. The molecule differs from endogenous GLP-1 at two key positions: an alpha-aminoisobutyric acid substitution at position 8 confers resistance to DPP-4 enzymatic degradation, and a C18 fatty-diacid side chain attached via a linker at lysine-26 enables greater than 99% albumin binding.^[8] The result is a plasma half-life of approximately 165 hours — compared with the 2-minute half-life of native GLP-1 — making once-weekly subcutaneous administration pharmacokinetically feasible.

The compound is FDA-approved for three indications as of 2025: type 2 diabetes management (subcutaneous and oral formulations), chronic weight management in adults and adolescents aged 12 and older, and metabolic dysfunction-associated steatohepatitis (MASH, accelerated approval August 2025).^[20] All formulations are prescription-only.

The clinical trial program spans more than 50,000 participants across six distinct development programs. Each is summarized in this console.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the endogenous incretin hormone GLP-1, which is released from intestinal L-cells after nutrient ingestion. GLP-1 receptors are expressed on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, hepatocytes, and cardiovascular tissue; semaglutide activates all of these targets.^[10]

The compound's molecular weight is 4,113.6 Da. Its sequence shares 94% homology with human GLP-1. Unlike earlier GLP-1 receptor agonists developed from exendin-4, semaglutide is a human-GLP-1 analogue modified specifically for extended half-life — not a reptilian peptide.

Two formulation classes exist. The subcutaneous injectable achieves bioavailability of approximately 89% and Tmax of 24-72 hours.^[8] The oral tablet uses sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) as an absorption enhancer; oral bioavailability is approximately 0.8%, requiring a 14 mg tablet to deliver therapeutically effective plasma concentrations. Oral semaglutide must be taken 30 minutes before the first meal of the day with water only.

GLP-1 receptor agonism was initially developed to improve glycemic control in type 2 diabetes. The connection to body weight came from early diabetes trials, in which treated subjects consistently lost more weight than expected — an effect driven by semaglutide's central appetite-suppression pathway, not by glycemic correction alone.

The STEP program tested semaglutide 2.4 mg subcutaneous once weekly specifically for weight management in people with obesity or overweight plus at least one weight-related comorbidity. STEP 1 enrolled 1,961 adults without diabetes; the 14.9% mean weight loss over 68 weeks was the primary endpoint.^[1] STEP 2 enrolled 1,210 adults with coexisting type 2 diabetes and found 9.6% weight loss — substantially more than the 7.0% achieved with the standard 1.0 mg diabetes dose and three times the 3.4% on placebo.^[4] STEP 5, a two-year trial in 304 adults, demonstrated that weight loss was sustained: mean 15.2% at week 104, with 77.1% of semaglutide participants maintaining at least 5% loss at two years.^[2]

Body composition data from a DXA substudy of STEP 1 (n=140) showed visceral fat mass reduced by 27.4% and total fat mass by 19.3% at week 68; lean body mass proportion relative to total mass increased by 3.0 percentage points, though absolute lean mass declined by approximately 10% — a finding relevant to sarcopenia risk in older adults that remains under investigation.^[11]

Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 20% in adults with obesity or overweight and established cardiovascular disease but without diabetes in the SELECT trial — a 17,604-person randomized controlled trial with a median 39.8-month follow-up period.^[5] Hazard ratio 0.80 (95% CI 0.72–0.90; p<0.001). SELECT was the first GLP-1 receptor agonist trial to demonstrate cardiovascular benefit in a population defined by obesity, not diabetes.

The earlier SUSTAIN-6 trial (n=3,297) demonstrated cardiovascular safety with an approximate 26% reduction in MACE in patients with type 2 diabetes and high cardiovascular risk over two years.^[6] Oral semaglutide demonstrated cardiovascular noninferiority in PIONEER 6 (n=3,183), with all-cause mortality significantly lower versus placebo (HR 0.51; p=0.008).^[7]

The cardiovascular outcomes research section details these findings side by side.

The semaglutide evidence base comprises six distinct clinical programs, each targeting a different indication or formulation:

• STEP program — Eight trials testing 2.4 mg subcutaneous for chronic weight management, covering obesity, T2DM, discontinuation (STEP 4), two-year efficacy (STEP 5), and adolescents aged 12–18 (STEP TEENS).
• SUSTAIN program — Nine trials testing subcutaneous 0.5–2.0 mg for type 2 diabetes. SUSTAIN-6 provided cardiovascular outcomes certification.^[6] SUSTAIN FORTE established 2.0 mg superiority.^[22]
• PIONEER program — Eleven trials testing oral semaglutide for type 2 diabetes. PIONEER 1 established oral efficacy as monotherapy.^[23] PIONEER 6 confirmed cardiovascular safety for the oral formulation.^[7]
• SELECT — Cardiovascular outcomes in obesity without diabetes (n=17,604).^[5]
• FLOW — Kidney disease outcomes in type 2 diabetes with chronic kidney disease (n=3,533).^[19]
• ESSENCE — MASH liver disease resolution outcomes in biopsy-confirmed MASH with fibrosis (FDA accelerated approval August 2025).^[20]